Ocugen Inc
Suletud
1.31 -3.68
Ülevaade
Aktsiahinna muutus
24h
Min
1.35
Max
1.37
Sissetulek | -1.5M -19M |
|---|---|
Müük | 1.7M 1.5M |
Aktsiakasum | -0.06 |
Kasumimarginaal | -1,250.946 |
Töötajad | 116 |
EBITDA | -987K -17M |
Soovitused | Tugev "osta" hinnang |
|---|---|
12 kuu keskmine prognoos | +611.03% upside |
Järgmine tulemuste avaldamine | 31. juuli 2026 |
|---|
Turukapital | -149M 477M |
|---|---|
Eelmine avamishind | 4.99 |
Eelmine sulgemishind | 1.31 |
Ocugen Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Ocugen Inc Prognoos
Hinnasiht
By TipRanks
611.03% tõus
12 kuu keskmine prognoos
Keskmine 9.67 USD 611.03%
Kõrge 12 USD
Madal 7 USD
Põhineb 6 Wall Streeti analüütiku instrumendi Ocugen Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Ocugen Inc
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
